- Home
- »
- Medical Devices
- »
-
Top 20 DFU Treatment Brands: Market Share, Pricing & Revenue InsightsGVR Report cover
Top 20 DFU Treatment Brands: Market Share, Pricing & Revenue Insights
Report Overview
The leading diabetic foot ulcer treatment brands continue to strengthen their market presence through high clinical adoption, strong reimbursement support, and broad utilization across multiple care settings. Products such as advanced foam dressings and antimicrobial wound care solutions from key manufacturers are experiencing significant adoption, reflecting growing physician preference and increasing demand for effective chronic wound management therapies. The following table highlights the major DFU treatment brands, along with their site-of-care penetration, reimbursement codes, adoption rates, and market share positioning in the competitive wound care landscape.
Top DFU Treatment Brands by Site of Care, Reimbursement Code, Adoption Rate & Market Share Insights
Manufacturer
Brand
Site of Care
Reimbursement Code
Adoption Rate (%)
Market Share (%)
Smith & Nephew
Allevyn Thin
Hospital Inpatient
A6209
95.0
10.0
Coloplast
Biatain Non-Adhesive
Hospital Inpatient
A6210
95.0
8.0
Hartmann
Cosmopor E
Hospital Inpatient
A6209
95.0
7.0
Essity
Cutimed Sorbact
Hospital Inpatient
A6209
95.0
6.0
Smith & Nephew
Allevyn Thin
Hospital Outpatient
A6209
95.0
10.0
Coloplast
Biatain Non-Adhesive
Hospital Outpatient
A6210
95.0
8.0
Hartmann
Cosmopor E
Hospital Outpatient
A6209
95.0
7.0
Essity
Cutimed Sorbact
Hospital Outpatient
A6209
95.0
6.0
Smith & Nephew
Allevyn Thin
Wound Care Center
A6209
95.0
10.0
Coloplast
Biatain Non-Adhesive
Wound Care Center
A6210
95.0
8.0
Hartmann
Cosmopor E
Wound Care Center
A6209
95.0
7.0
Essity
Cutimed Sorbact
Wound Care Center
A6209
95.0
6.0
Smith & Nephew
Allevyn Thin
Home Healthcare
A6209
95.0
10.0
Coloplast
Biatain Non-Adhesive
Home Healthcare
A6210
95.0
8.0
Hartmann
Cosmopor E
Home Healthcare
A6209
95.0
7.0
Essity
Cutimed Sorbact
Home Healthcare
A6209
95.0
6.0
Source: GVR Analysis
The leading diabetic foot ulcer (DFU) treatment brands continue to strengthen their market presence through high clinical adoption, strong reimbursement support, and broad utilization across multiple care settings. Products such as advanced foam dressings and antimicrobial wound care solutions from key manufacturers are experiencing significant adoption, reflecting growing physician preference and increasing demand for effective chronic wound management therapies. The following table highlights the major DFU treatment brands, along with their site-of-care penetration, reimbursement codes, adoption rates, and market share positioning in the competitive wound care landscape.
Executive Summary
Diabetic foot ulcers (DFUs) are becoming a significant clinical and economic burden, creating strong demand for advanced wound care therapies that improve healing outcomes and reduce amputation risks. The DFU treatment market is evolving rapidly due to the rising prevalence of diabetes, the growing chronic wound burden, and the increasing adoption of advanced wound care solutions such as biologics, skin substitutes, and negative-pressure wound therapy products across hospitals, wound care centers, outpatient clinics, and home healthcare settings.
This report provides a detailed analysis of the top 20 DFU treatment brands, assessing market share, pricing trends, reimbursement dynamics, units utilized per patient, and revenue performance. It further highlights competitive positioning, utilization patterns, and emerging growth trends shaping the future of the DFU treatment industry.
-
According to the latest International Diabetes Federation (IDF) Diabetes Atlas 2025, approximately 11.1% of the global adult population aged 20-79 years, equivalent to 1 in 9 adults, is living with diabetes, with more than 40% of cases remaining undiagnosed.
-
By 2050, the global diabetic population is projected to reach approximately 853 million adults, meaning nearly 1 in 8 adults worldwide will be living with diabetes, representing a 46% increase compared to current levels.

If diabetic foot ulcers (DFUs) are not treated effectively, they can worsen over time and eventually lead to lower-limb amputation. The amputations also have severe physical and psychological impacts on patients, often reducing mobility and quality of life. DFUs are associated with a higher five-year mortality rate than several cancers, including prostate, breast, and Hodgkin lymphoma. The risk becomes even more severe following minor or major amputations, with mortality rates rising to levels comparable to those seen in lung and pancreatic cancers.

Competitive Intelligence: Brand & Manufacturer Analysis
The competitive landscape in the diabetic foot ulcer (DFU) wound care market is characterized by leading manufacturers competing on clinical efficacy, reimbursement support, pricing strategies, and site-of-care penetration. Companies are focusing on advanced biologics, skin substitutes, and negative pressure wound therapy technologies to strengthen market positioning and expand physician adoption. Competitive intelligence analysis further highlights differences in portfolio strength, utilization trends, reimbursement advantage, and commercialization strategies among key DFU treatment brands.

Innovation Landscape and Competitive Positioning of Leading Diabetic Foot Ulcer Treatment Brands
Core Innovation Segment
Leading Brands
Primary Manufacturers
Innovation Driver
Market Positioning
Advanced Biologics & Regenerative Grafts
Apligraf, EpiFix, Kerecis Omega3
Organogenesis, MiMedx, Coloplast
Use of living cells, placental tissue, or fish-skin scaffolds to reset the chronic wound cycle.
Premium Value: Targeted at high-risk, "non-healing" ulcers to prevent amputation.
Smart & Single-Use Therapy Devices
V.A.C. Ulta, PICO, OptiPulse
3M (Solventum), Smith+Nephew, Compedica
Remote wound monitoring and portable, canister-less Negative Pressure (NPWT) systems.
Market Leader: Designed to bridge the transition from hospital to home-care settings.
Active Physiological Stimulators
Dermapace
SANUWAVE
Continuous topical oxygen delivery or acoustic shockwaves trigger angiogenesis.
High Growth: Niche solutions for ischemic ulcers with severely poor circulation.
Digital Health & AI Diagnostics
Swift Medical, Healthy.io
Swift Medical, Healthy.io
Smartphone-based 3D wound measurement and AI-driven tissue analysis.
Disruptor: Provides objective data required to secure reimbursement for high-cost therapies.
KoL Perspectives & Clinical Insights
KOL perspectives and clinical insights are critical for understanding evolving treatment preferences, adoption patterns, and unmet needs in diabetic foot ulcer (DFU) wound care management. Expert opinions from wound care specialists and clinicians provide valuable insights into product efficacy, reimbursement challenges, treatment selection criteria, and emerging therapeutic trends shaping the DFU care landscape.
“Our strategic investment in Siren reflects our commitment to integrating into digital ecosystems and pioneering innovative digital solutions that revolutionise healthcare delivery,” and continues “Helping to prevent wounds from occurring is also in line with Mölnlycke’s Wound Care mission to ‘help free patients from the burden of wounds’ and our ambition to further support healthcare in the post-acute segment.” - said Zlatko Rihter, CEO of Mölnlycke
“We’re excited to team up with Mölnlycke to tackle diabetic foot ulcers at their earliest stages”. “By investing in preventive technologies like ours, Mölnlycke is demonstrating real vision and leadership in helping patients avoid the debilitating consequences of diabetic foot ulcers. Their investment sends a clear message that prevention matters. By catching issues before they escalate, we can help patients stay healthy and independent, reduce unnecessary procedures, and ultimately make a real difference in their lives.” - said Ran Ma, co-founder and CEO of Siren.
The launch of ColoNoX marks a significant advancement in addressing the urgent need for effective and affordable diabetic foot ulcer (DFU) treatments in India. He added, “This initiative reflects our commitment to the motto ‘राष्ट्रकीसेवामेंपरमाणु’ (Atoms in the service of the nation), where we strive to harness scientific innovation for the betterment of society.” This also exemplifies the Government of India’s initiative of ‘Making in India’ and ‘Make for the World.’ Shri Vivek Bhasin, Director, BARC, praised the collaborative efforts of scientists from BARC and Cologenesis Healthcare Pvt. Ltd. for successfully translating this innovation from the laboratory to commercial reality as ColoNoX. This will positively improve the treatment of diabetic foot ulcer and will minimize damage to foot. - said Dr. Ajit Kumar Mohanty, Secretary, DAE and Chairman AEC
"In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their quality of life. To address the problem, Alkem has collaborated with Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions for the management of diabetic foot ulcers." - said Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd.
"Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives." - said Mr. Sandeep.
“The challenges facing wound care require more than incremental change. At EWMA 2026, Convatec will demonstrate how our deep, diversified and evidence-led innovation pipeline will meaningfully advance healing and reshape clinical practice through Wound Hygiene. Underpinned by 30 years of Hydrofibe technology, rigorous clinical evidence and Convatec’s strongest ever wound care pipeline, we are leading the industry in advanced wound care to meet the needs of patients and healthcare professionals worldwide.” - said Tanja Dormels, President, Advanced Wound Care at Convatec.
“Diabetic foot ulcers are one of the leading causes of mortality, morbidity, and lower extremity amputations in patients with diabetes, and the medical community continuously strives to identify novel therapies to prevent or reduce these complications and their significant burden to patients, families, and the healthcare system at large,” said Dr. Richard Simman, Professor of Plastic Surgery at the University of Toledo College of Medicine, Jobst Vascular Institute at ProMedica Health System in Toledo, Ohio. ProMedica conducted the DFU clinical trial.
“We’re extremely encouraged by the final results of our clinical trial evaluating Omeza’s OCM platform, which showed significant healing-and in over half the cases, complete closure-of patients’ diabetic wounds in twelve weeks or less. This is a notable achievement, given the resistance to standard treatments that DFUs often display,” said Simman, principal investigator at the ProMedica clinical trial site.
Strategic Trends
-
Biologics Expanding into Earlier Treatment Lines
-
Smart Wound Monitoring and Remote Care Adoption
-
AI-Driven Clinical Decision Support Systems
-
Rapid Shift Toward Homecare-Based Treatment
-
Asia-Pacific Emerging as a High-Growth Regional Market
-
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.